On Biostatistics and Clinical Trials

CQ's web blog on the issues in biostatistics and clinical trials.

Sunday, June 05, 2016

Difference between Precision Medicine and Personalized Medicine?

›
A friend of mine asked me about the difference between ‘personalized medicine’ and ‘precision medicine’. Just a couple of years ago, the te...
Sunday, May 22, 2016

Placebo Effect and The Choice of Placebo

›
Recently, NPR had a discussion about the influence of Placebo effect on consumer product purchases .   While the concept of the placebo ef...
1 comment:
Monday, May 02, 2016

Dose Cohort Expansion Study - A Never Ending Phase I Study Design

›
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question. In Phase...
1 comment:
Sunday, May 01, 2016

Free SAS e-learning courses in Programming 1 and Statistics 1

›
Great news to new SAS learners! SAS have made their introductory e-learning courses available to everyone at no cost. Don’t miss this chanc...
1 comment:
Monday, April 25, 2016

Communications Between DMC (Data Monitoring Committees) and Regulatory Authorities

›
In the recent issue of NEJM.org, Karl Swedberg, M.D., Ph.D et al wrote an article “ Challenges to Data Monitoring Committees When Regulator...
Friday, April 15, 2016

Race for the first drug approval by FDA for treating Duchenne Muscular Dystrophy (DMD)

›
Duchenne muscular dystrophy (DMD) is an inherited disorder that involves   muscle weakness , which quickly gets worse. Duchenne muscular dy...
Friday, April 01, 2016

Submitting Individual Patient or Subject's Case Report Forms to FDA

›
When submitting the NDA (new drug application) or BLA (biological license application) to FDA, as part of the CTD (common technical documen...
2 comments:
Thursday, March 24, 2016

Protocol Template for Clinical Trials

›
For any clinical trial, the study protocol is the most critical document and is the blueprint of the entire study. There are clinical studi...
Monday, March 14, 2016

Targeted or Selective Safety Data Collection in Late Pre-authorisation and Post-authorisation Clinical Trials.

›
Last month, FDA released its final guidance " Guidance for Industry: Determining the Extent of Safety Data Collection Needed in Late-St...
‹
›
Home
View web version

About Me

My photo
Web blog from Dr. Deng
Chapel Hill, NC, United States
邓春勤 A Medical Doctor turned into Biostatistician in Clinical Trial and Drug Development Industry
View my complete profile
Powered by Blogger.